Business Description
Corline Biomedical AB
ISIN : SE0006887451
Total Employee Number:
13Compare
Compare
Traded in other countries / regions
CLBIO.SwedenIZ7.Germany IPO Date
2026-03-27Description
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.87 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 15.66 | |||||
Beneish M-Score | -1.8 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -33.9 | |||||
3-Year FCF Growth Rate | -2.4 | |||||
3-Year Book Growth Rate | -6 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.84 | |||||
9-Day RSI | 44.65 | |||||
14-Day RSI | 46.26 | |||||
3-1 Month Momentum % | 11.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.41 | |||||
Quick Ratio | 6.28 | |||||
Cash Ratio | 5.14 | |||||
Days Inventory | 282.74 | |||||
Days Sales Outstanding | 84.58 | |||||
Days Payable | 446.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6 | |||||
Shareholder Yield % | -2.02 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89.32 | |||||
Operating Margin % | -143.45 | |||||
Net Margin % | -143.06 | |||||
EBITDA Margin % | -142.25 | |||||
FCF Margin % | -189 | |||||
OCF Margin % | -177.12 | |||||
ROE % | -16.23 | |||||
ROA % | -14.96 | |||||
ROIC % | -17.94 | |||||
3-Year ROIIC % | -235.41 | |||||
ROC (Joel Greenblatt) % | -5834.57 | |||||
ROCE % | -15.89 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 44.52 | |||||
PB Ratio | 4.54 | |||||
Price-to-Tangible-Book | 17.17 | |||||
EV-to-EBIT | -29.46 | |||||
EV-to-EBITDA | -29.63 | |||||
EV-to-Revenue | 42.14 | |||||
EV-to-FCF | -22.61 | |||||
Price-to-GF-Value | 3.43 | |||||
Price-to-Median-PS-Value | 0.78 | |||||
| Price-to-Net-Current-Asset-Value | 17.17 | |||||
| Price-to-Net-Cash | 25.75 | |||||
Earnings Yield (Greenblatt) % | -3.39 | |||||
FCF Yield % | -4.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Corline Biomedical AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.909 | ||
| EPS (TTM) (€) | -0.052 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 46.26 | ||
| 14-Day ATR (€) | 0.031244 | ||
| 20-Day SMA (€) | 1.57475 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 1.34 - 1.715 | ||
| Shares Outstanding (Mil) | 26.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Corline Biomedical AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Corline Biomedical AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-16 | In 125 days | ||
| Second quarter earnings results for 2026 | 2026-08-26 | In 43 days | ||
| General meeting for 2026 | 2026-05-12 15:00 | 1.55 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 1.40 (+0.00%) | ||
| Annual report for 2025 | 2026-04-21 | 1.56 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-17 | -- | ||
| Third quarter earnings results for 2025 | 2025-11-18 | -- | ||
| Second quarter earnings results for 2025 | 2025-08-26 | -- | ||
| General meeting for 2025 | 2025-05-15 10:00 | -- | ||
| First quarter earnings results for 2025 | 2025-05-08 | -- |
Show
Entries
Corline Biomedical AB Frequently Asked Questions
What is Corline Biomedical AB(FRA:IZ7)'s stock price today?
The current price of FRA:IZ7 is €1.55. The 52 week high of FRA:IZ7 is €1.72 and 52 week low is €1.34.
When is next earnings date of Corline Biomedical AB(FRA:IZ7)?
The next earnings date of Corline Biomedical AB(FRA:IZ7) is 2026-08-26.
Does Corline Biomedical AB(FRA:IZ7) pay dividends? If so, how much?
Corline Biomedical AB(FRA:IZ7) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Corline Biomedical AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers